Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Vanderbilt University Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05312892CT.gov Sympathetic Mechanisms in Obesity-Crossover Design | — | Recruiting | — | — | — |
NCT04023565CT.gov Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome | — | Unknown | — | — | — |
NCT04474899CT.gov Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension | — | Unknown | — | — | — |
NCT01360710CT.gov The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension | — | Unknown | — | — | — |
NCT01138423CT.gov Treatment of Adiposity Related hypErTension (TARGET) | — | Completed | — | — | — |
NCT05147753CT.gov Moxonidine Effects on Neuropeptide Y | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertensive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Moxonidine (this asset) | Vanderbilt University Medical Center | Approved | BB · 71 |
| Valsartan | University of Alabama at Birmingham | P4 | BBB |
| Hydrochlorothiazide | University of Kansas Medical Center | P4 | BBB |
| Losartan | Rong Zhang | P4 | BBB |
| Amlodipine | Jing Liu | P4 | BBB |
| Corpril | University of Michigan | P4 | BBB |
| Trandolapril | University of Florida | P4 | BBB |
| Olmesartan Medoxomil | Virginia Polytechnic Institute and State University | P4 | BBB |
| Verapamil Slow Release | Abbott | P4 | BBB |
+42 more in the Hypertensive Disorder cohort
Other indications for Moxonidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BB · 66 |
| Polycystic Ovary Syndrome | — | P4 | B · 62 |
| Obesity Disorder | — | P4 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Moxonidine in Hypertensive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/moxonidine-hypertensive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →